Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
September 6
Marc CHALLANDE
Maybe you haven’t noticed it, but Fandifi (FMD.CN)’s volume has incredibly augmented on August 2, and it’s caught the eye of many investors. Indeed almost 400,000 shares were traded during last week’s session, worth five times more than usual sessions (the daily average is 77k). As you might read on investors’ forums, “is there something brewing”? Was a piece of relevant information shared during the last company’s webinar? Until we discover the following news release, it would be great to do a small recap of the company’s previous highlights.
Fandifi Technology is a pure, innovative tech play. On the one hand, the company builds a crowd-based and system-generated prediction and fan engagement platform. On the other hand, Fandifi operates an NFT marketplace where rewards can be bought, sold, or traded on an interoperable blockchain agnostic platform.
Why is it very strategic to hold an engagement platform? In our modern era, streaming platforms appear to be the new media winners. The Wall Street Journal states, “Sports leagues, especially Major League Baseball, are seeing declines in younger viewership. The change comes as people turn away from traditional TV viewing and toward social media, video games, and streaming TV”. Numbers approve the trend. Western game streaming reached 8.8 billion hours viewed in Q1, representing an 80% increase year-over-year. In the USA, back in June 2021, cable television accounted for 40.1% of all video viewing. One year later, cable’s share had dropped by five points to 35.1%.
Conversely, in June 2022, streaming video exceeded one-third (33.7%) of all video viewing for the first time, a sizable increase from the 27.4% share just one year ago. The viewing share of streaming video has risen every month since March increasing four share points during that time. The shares of broadcast television stood at 22.4% in June, the lowest over the past twelve months.
Fandifi’s unique technology brings engagement for creators and fans that enables deeper connections with live content through several platforms. The company has built the leading Fan Engagement prediction technology that encourages and rewards users for being the most significant & wisest fans. Fandifi’s platform turns casual fans into Superfans by allowing them to become part of the action going head to head with other fans in support of their favorite content creator or team. To reach a broader audience, the company operates on Android and IOS mobile devices and has an Exclusive Sports & Esports license for purpose -built Unified Information Access (UIA) platform. In simple words, it is the league for the fans.
“Fandifi empowers global content creators with a unique crowd-based and system-generated prediction engine that increases fan engagement and satisfaction through unique content.”
David Vinokurov (CEO) leads the company. David is a seasoned capital markets professional involved in numerous aspects of corporate management and deploying capital market strategies for publicly listed companies. David is a focused, determined, competent member of management and advisory boards of companies in the gaming, esports, gaming, technology, fintech, and natural resource sectors.
On August 11, Fandifi hosted a webinar presented by David Vinokurov (CEO & president). David Vinokurov presented the company’s story, including an overview of current operations and upcoming milestones. He also provided a live demonstration of the Fandifi platform highlighting the prediction and gamification capabilities for streamed and broadcast content. Once the presentation was done, investors we able to ask many questions. One of the most interesting ones was about partnerships. David Vinokurov said they would arrive soon. All we need is an official news release to state this declaration.
On May 31, the company announced It had entered into an affiliate marketing and business development agreement with Blockgration Global Corp. This company provides access to a digital asset platform that can provide liquidity to investors and companies operating in its ecosystems. Blockgration currently owns and deploys a diversified set of blockchain as a service (BaaS) solutions that can be customized for different vertical industries. Their proprietary processing platform integrates multiple product-based operational applications to provide one-stop solutions to strategic partners, clients, investors, and customers.
“Blockgration’s existing platform deployment in Indonesia, India, and the Philippines give us a toe hold in new markets and a strong presence on the ground with local partners to expand and grow the Fandifi footprint.”
David Vinokurov, Fandifi CEO and President
-Fandifi (FMD.CN) saw its volume increasing without news suggesting a possible rebound;
-The company is also expanding to Asia, meaning Fandifi is targeting a worldwide use of its platforms;
-Once the company has partnerships, it will lead to a substantial increase in revenue + new partnership opportunities;
-The stock price remains low/undervalued, but many technical indicators mention the stock is currently a BUY.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts